Table 3. Univariate and multivariable logistical regression evaluating factors associated with pCR.
| Univariate analysis | Multivariable analysisa | |||||
|---|---|---|---|---|---|---|
| OR | CI 95% | p | OR | IC 95% | p | |
| Age at Dx | 1.0 | 0.98–1.02 | 0.76 | - | - | - |
| BMI |
0.98 | 0.93–1.05 | 0.62 | - | - | - |
| Clinical stage (TNM) I–II III |
- 1.05 |
- 0.66–1.66 |
- 0.84 |
- | - | - |
| Compromised LN (yes) | 0.88 | 0.51–1.54 | 0.66 | - | - | - |
| Ki67 | 1.01 | 0.99–1.02 | 0.10 | - | - | - |
| HR positive | 0.30 | 0.19–0.48 | <0.001b | 0.31 | 0.17–0.57 | <0.001b |
| HER2 positive | 3.50 | 2.22–5.47 | <0.001b | 5.26 | 2.92–9.50 | <0.001b |
| Subgroup by receptors HR+/HER2−HR+/HER2+ HR−/HER2+ HR−/HER2− |
- 3.32 9.96 3.14 |
- 1.70–6.50 5.16–19.24 1.60–6.17 |
- <0.001b <0.001b 0.001b |
- - - - |
- - - - |
- - - - |
| FHx of cancer | 2.81 | 1.61–4.91 | <0.001b | 2.31 | 1.23–4.35 | 0.009b |
| NeoCT regime Anthracyclines only Taxanes only Anthracyclines and Taxanes |
- 21.8 19.8 |
- 2.31–205.9 2.70–145.8 |
- 0.007b0.003b |
- 7.82 13.2 |
- 0.48–127.6 1.65–104.7 |
- 0.15 0.01b |
a
In the multivariate analysis, only those factors were considered which were significant in the first analysis
b
Statistical significance (p < 0.05)Dx: Diagnosis, LN: lymph nodes, BMI: body mass index (weight/height2), HFx: family history, BC: breast cancer, HR: hormone receptor